title: Current opinions and controversies in chronic myeloid leukaemia.
abstract: OBJECTIVE
  The prognosis of chronic myeloid leukaemia (CML) has improved remarkably over the last 11 years with the introduction of tyrosine kinase inhibitors (TKIs) in clinical practice. Here we intend to focus on clinically based problems and their solution based on the evidence from literature and our experience as a centre for excellence.
  
  
  RESULTS
  Recent results from trials with first and second generation TKIs have help to clarify some, but not all, of the common clinical dilemmas that physicians face when treating CML patients.
  
  
  CONCLUSIONS
  CML treatment received a paradigm shift with the launch of TKIs. However, questions remain about adherence, tolerability, toxicity, resistance, and management and about the selection of second-generation drugs and the interpretion of responses and the role of stem cell transplantation.
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: Bhuvan
authors.initials: B
authors.lastname: Kishore
authors.forename: David
authors.initials: D
authors.lastname: Marin
mesh_terms: D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases